Send me a link:

*Text messaging rates may apply.

 Dow Down0.63% Nasdaq Down0.89%




News & Info


Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates


  • Major Holders
  • Insider Transactions
  • Insider Roster


  • Income Statement
  • Balance Sheet
  • Cash Flow

ThromboGenics NV (TBGNF)

-Other OTC
13.45 0.00(0.00%) Jul 24
ProfileGet Profile for:
ThromboGenics NV
Gaston Geenslaan 1
Leuven, 3001
Belgium - Map
Phone: 32 1 675 13 10
Fax: 32 1 675 13 11

Index Membership:N/A
Full Time Employees:154

Business Summary 

ThromboGenics NV, an integrated biopharmaceutical company, is engaged in developing and commercializing ophthalmic and oncology medicines in Belgium and interntionally. The company offers JETREA for the treatment of symptomatic vitreomacular traction. It has a collaboration agreement with BioInvent International AB to develop anti-factor VIII, an anti-coagulation treatment for various indications, such as the prevention and treatment of deep vein thrombosis, and the treatment of atrial fibrillation; and anti-placental growth factor, an anti-angiogenic component for the treatment of various disorders, including cancer, age-related macula degeneration, retinopathy, and inflammation. The company also has a research and license agreement with Bharat Biotech; a production agreement with Fujifilm Diosynth Biotechnologies UK Limited; a license agreement Grifols and NuVue Technologies, Inc.; a life sciences research partnership with VZW; agreements with Eleven Biotherapeutics, Bicycle Therapeutics, and Flanders Institute for Biotechnology; and cooperation agreements with Centrum voor Moleculaire en Vasculaire Biologie and KULeuven. ThromboGenics NV was founded in 1991 and is headquartered in Leuven, Belgium.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on ThromboGenics NV

Key Executives 
Dr. Patrik De Haes ViBio, BVBA,
Chief Exec. Officer and Exec. Director
Mr. Luc Philips , 63
Interim Chief Financial Officer, Non-Exec. Independent Director and Chairman of Audit Committee
Mr. Claude Sander ,
Corp. Compliance Officer and Gen. Counsel
Mr. Wouter Piepers ,
Head of Corp. Communications
Mr. David C. Pearson Ph.D.,
Global Head of Corp. Devel.
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.